CD44 and neoplasm: Our HA-capped AuNPs exhibited an enhanced inhibitory activity against Escherichia coli ATCC 9637 and Staphylococcus aureus ATCC 29213 as well as a better targeted cytotoxicity towards CD44-positive tumor cells than the bare, glucose-capped, AuNPs (Table 4).